| Literature DB >> 18238951 |
M Cazzola1, W MacNee, F J Martinez, K F Rabe, L G Franciosi, P J Barnes, V Brusasco, P S Burge, P M A Calverley, B R Celli, P W Jones, D A Mahler, B Make, M Miravitlles, C P Page, P Palange, D Parr, M Pistolesi, S I Rennard, M P Rutten-van Mölken, R Stockley, S D Sullivan, J A Wedzicha, E F Wouters.
Abstract
The American Thoracic Society/European Respiratory Society jointly created a Task Force on "Outcomes for COPD pharmacological trials: from lung function to biomarkers" to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers when evaluating the impact of a pharmacological therapy. Based on their review of the published literature, the following document has been prepared with individual sections that address specific outcomes and markers, and a final section that summarises their recommendations.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18238951 DOI： 10.1183/09031936.00099306
Source DB: PubMed Journal: Eur Respir J ISSN： 0903-1936 Impact factor: 16.671